A First-in-Human Phase 1/2 Study of SAR449336, an Oral Non-Covalent Pan-KRAS Inhibitor, in Patients With Advanced KRAS-Mutant Solid Tumors (Trial in Progress)

SAR449336 - Blueprint Medicines, Sanofi

https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal_2/print/presentation/6180

Alexander I. Spira; David S. Hong; Salman R. Punekar; Harshabad Singh; Ilda Bidollari; Benjamin Lampson; Chia-cheng Li; Isabel Anacleto; Kevin He; Ignacio Garrido-Laguna

Jul 17, 2026